Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Humanigen"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The patent covers the use of lenzilumab to prevent or treat cytokine release syndrome (CRS), neurotoxicity and otherwise inhibit or reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy.

            Lead Product(s): Lenzilumab

            Therapeutic Area: Pharmacology/Toxicology Product Name: Humaneered

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 28, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY